Sun Pharmaceutical Share Price Today | Stock Price & Sun Pharmaceutical Share Screener
As of October 22, 2026, the live Sun Pharmaceutical share price (NSE: SUNPHARMA) is ₹1,758.00 on NSE and ₹1,743.00 on BSE, up 0.74% from the previous close, with shares trading between ₹1,719.10 and ₹1,758.00 in today's trading session, and a 52-week range of ₹1,589.30–₹2,001.10. Check SUNPHARMA 52-week performance for the annual price range and momentum. Use the Sun Pharmaceutical stock screener below to analyse P/E ratio, market cap, quarterly results, and more. See at what price today Sun Pharmaceutical opened, then compare its market price and price volume with top gainers and top losers on the exchange. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Key Statistics and Valuation Ratios
Over the trailing twelve months the company reported revenue of ₹15,907 and net income of ₹2,901, with EBITDA of ₹4,821, an operating margin of 27.0% and a profit margin of 18.2%.
Sun Pharmaceutical Share Price Chart
Track the current stock price of Sun Pharmaceutical with an interactive chart. Analyse SUNPHARMA share price trends, closing price, trading volume, historical performance, and volatility using live market data across different timeframes, from the last 30 days to the full record — the complete Sun Pharmaceutical stock quote in one place.
The quote of ₹1,758.00 sits between the 52-week low of ₹1,589.30 and the 52-week high of ₹2,001.10, and the latest session moved 0.74% from the previous close.
Sun Pharmaceutical Company Profile - Fundamental Screener
Screen Sun Pharmaceutical company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for SUNPHARMA shares across the equity market and its stock price history, plus the wider market trend.
The company is classified under the Healthcare sector and the Pharmaceuticals industry, with Dilip S Shanghvi listed as chairperson or CEO, and it trades under ISIN INE044A01036.
Business Overview
Sun Pharmaceutical Industries Limited is a global specialty generic pharmaceutical company based in India. It manufactures and markets a wide range of pharmaceutical formulations including generics, branded generics, complex products, over-the-counter drugs, and active pharmaceutical ingredients. The company has a diverse portfolio covering multiple therapeutic areas and dosage forms. Sun...more
Company Details
Classification
Identifiers and Leadership
Sun Pharmaceutical Balance Sheet Screener
Screen SUNPHARMA balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics, then compare equity shares and the debt-to-equity rate against peers in the stock market.
For 2026, total assets were ₹108,785, up from ₹92,101 in 2025.
Latest statistics put total assets at ₹108,785 and shareholder funds at ₹83,880, with a leverage ratio of 0.04.
| Item | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
Assets |
||||||||||
| Total Assets | 108,785 | 92,101 | 85,500 | 80,744 | 69,808 | 67,667 | 68,253 | 64,694 | 64,516 | 61,410 |
| Current Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Fixed Assets | 32,822 | 22,586 | 23,248 | 24,065 | 22,665 | 21,553 | 22,847 | 21,837 | 18,853 | 17,675 |
Liabilities |
||||||||||
| Total Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Liabilities | 2,283 | 1,420 | 1,390 | 1,522 | 1,533 | 2,041 | 3,421 | 2,632 | 2,454 | 3,093 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Shareholders' Equity |
||||||||||
| Total Equity | 83,880 | 72,486 | 67,126 | 59,316 | 51,066 | 49,480 | 49,125 | 44,723 | 42,198 | 40,431 |
| Share Capital | 240 | 240 | 240 | 240 | 240 | 240 | 240 | 240 | 240 | 240 |
| Reserves & Surplus | 83,330 | 71,978 | 63,427 | 55,755 | 47,771 | 46,223 | 45,025 | 41,169 | 38,074 | 36,400 |
Sun Pharmaceutical Income Statement Screener - Profit & Revenue Analysis
Screen Sun Pharmaceutical income statement and profit fundamentals. Analyze SUNPHARMA quarterly results. Sun Pharmaceutical reports revenue growth, EBITDA, net profit margins, and EPS, and TickJournal's fundamental screener helps with stock evaluation and equity returns.
For 2026-Jun, revenue was ₹15,907 and net profit was ₹2,901, equal to earnings per unit of ₹12.10, at an operating margin of 27%.
In that period expenses were ₹11,086, interest cost ₹100 and tax ₹1,198. The next period listed, 2026-Mar, shows revenue of ₹15,018 and net profit of ₹2,710.
| Item | 2026-Jun | 2026-Mar | 2025-Dec | 2025-Sept | 2025-Jun | 2025-Mar | 2024-Dec | 2024-Sept | 2024-Jun | 2024-Mar | 2023-Dec | 2023-Sept | 2023-Jun | 2023-Mar | 2022-Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue and Expenses | |||||||||||||||
| Revenue | 15,907 | 15,018 | 16,048 | 14,875 | 14,251 | 13,429 | 13,903 | 13,618 | 13,057 | 12,419 | 12,407 | 12,297 | 11,990 | 11,099 | 11,274 |
| Expenses | 11,086 | 10,658 | 11,062 | 9,951 | 10,368 | 9,604 | 9,983 | 9,352 | 9,045 | 9,049 | 8,974 | 9,013 | 8,932 | 8,300 | 8,237 |
Operating Costs and Margins | |||||||||||||||
| EBITDA | 4,821 | 4,361 | 4,986 | 4,924 | 3,883 | 3,824 | 3,920 | 4,266 | 4,012 | 3,370 | 3,433 | 3,284 | 3,058 | 2,799 | 3,037 |
| Operating Profit % | 27.00% | 27.00% | 28.00% | 31.00% | 25.00% | 25.00% | 26.00% | 29.00% | 28.00% | 23.00% | 26.00% | 25.00% | 24.00% | 23.00% | 26.00% |
| Depreciation | 739 | 776 | 732 | 730 | 701 | 664 | 631 | 626 | 655 | 650 | 622 | 633 | 651 | 672 | 660 |
| Interest | 100 | 86 | 78 | 100 | 75 | 49 | 52 | 69 | 62 | 74 | 35 | 49 | 81 | 93 | 46 |
Profit and Earnings | |||||||||||||||
| Profit Before Tax | 4,099 | 3,551 | 4,227 | 4,168 | 3,173 | 3,254 | 3,476 | 3,598 | 3,424 | 2,816 | 3,000 | 2,791 | 2,481 | 2,240 | 2,472 |
| Tax | 1,198 | 842 | 846 | 1,043 | 880 | 1,100 | 563 | 561 | 563 | 157 | 440 | 406 | 476 | 257 | 291 |
| Net Profit | 2,901 | 2,710 | 3,381 | 3,125 | 2,293 | 2,154 | 2,913 | 3,037 | 2,861 | 2,659 | 2,561 | 2,385 | 2,006 | 1,983 | 2,181 |
| EPS | 12.10 | 11.30 | 14.00 | 13.00 | 9.50 | 9.00 | 12.10 | 12.70 | 11.80 | 11.10 | 10.50 | 9.90 | 8.40 | 8.30 | 9.00 |
Sun Pharmaceutical Cash Flow Screener - Liquidity Fundamentals
Screen SUNPHARMA cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength and price trend assessment against the wider stock market and other stocks.
In 2026-March, operating activities generated ₹12,419, and net cash flow was an outflow of ₹498.
Over the same period, investing activities used ₹10,405 and financing activities used ₹2,513.
| Item | 2026-March | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations and Investing | ||||||||||
| Operating Activities | 12,419 | 14,072 | 12,135 | 4,959 | 8,985 | 6,170 | 6,555 | 2,196 | 3,907 | 7,082 |
| Investing Activities | -10,405 | -5,183 | -763 | -7,220 | -5,556 | 407 | -2,225 | -310 | -3,104 | -4,186 |
Financing and Net Cash | ||||||||||
| Financing Activities | -2,513 | -7,906 | -6,710 | 2,376 | -5,194 | -5,981 | -5,715 | -2,731 | -1,539 | -2,285 |
| Net Cash Flow | -498 | 983 | 4,662 | 116 | -1,765 | 596 | -1,386 | -844 | -736 | 611 |
Sun Pharmaceutical Shareholding Pattern Screener
See Sun Pharmaceutical shareholding pattern with promoter, FII, and DII holdings. Check Sun Pharmaceutical promoter holding and ownership changes for SUNPHARMA on TickJournal, and see how institutional stock price moves affect the market.
In 2026-Sept, promoters held 52.68%, foreign institutions 14.36%, domestic institutions 22.27% and the public 6.71%, spread across 714,266 shareholders.
The shareholder count was 714,266 in 2026-Sept, compared with 710,246 in 2026-Jun.
| Item | 2026-Sept | 2026-Jun | 2026-Mar | 2025-Dec | 2025-Mar | 2025-Jun | 2025-Sept | 2024-Mar |
|---|---|---|---|---|---|---|---|---|
Promoter Holding | ||||||||
| Promoter Holding | 52.68% | 54.48% | 54.48% | 54.48% | 54.48% | 54.48% | 54.48% | 54.48% |
Institutional Investors | ||||||||
| FII Holding | 14.36% | 14.53% | 15.93% | 16.12% | 17.96% | 17.26% | 16.55% | 17.72% |
| DII Holding | 22.27% | 22.18% | 21.11% | 20.82% | 18.70% | 19.50% | 20.24% | 18.83% |
Government, Public and Others | ||||||||
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 6.71% | 5.48% | 5.30% | 5.40% | 5.42% | 5.35% | 5.53% | 5.44% |
| Other Holding | 3.99% | 3.33% | 3.18% | 3.18% | 3.45% | 3.42% | 3.20% | 3.53% |
| Shareholder Count | 714,266 | 710,246 | 690,957 | 710,900 | 704,983 | 723,770 | 743,877 | 631,392 |
Dividend Yield Screener - Share Price & Share Analysis
Check the dividend history with payout and yield data. View dividend details including ex-dates, the dividend rate, and amounts paid by Sun Pharmaceutical. Sun Pharmaceutical dividend yield can be compared with peers and other stocks in the market.
The latest dividend recorded was ₹16.00 per unit for 2026-March, a yield of 0.91%, compared with ₹16.00 for 2025-March.
Dividends are listed for 10 periods, with the three most recent payouts at ₹16.00, ₹16.00 and ₹13.50 per unit.
| Period | Dividend Per Share | Dividend Yield |
|---|---|---|
| 2026-March | ₹16.00 | 0.91% |
| 2025-March | ₹16.00 | 0.91% |
| 2024-March | ₹13.50 | 0.78% |
| 2023-March | ₹11.50 | 0.71% |
| 2022-March | ₹10.00 | 1.01% |
| 2021-March | ₹7.50 | 0.82% |
| 2020-March | ₹4.00 | 0.67% |
| 2019-March | ₹2.75 | 0.78% |
| 2018-March | ₹2.00 | 0.42% |
| 2017-March | ₹3.50 | 0.71% |
Sun Pharmaceutical Stock Index Membership - Nifty & Sensex
See which indices include Sun Pharmaceutical stock. Check SUNPHARMA index membership in NIFTY 50, SENSEX, and other indices on TickJournal, and compare the Nifty trend with the broader market trend.
The company is listed in 50 indices, including BSE 1000.
Among the benchmarks tracked are BSE 1000, BSE 200 EQUAL WEIGHT, BSE INDEX BSE HC, BSE INDEX BSE100.
Complete Index List
Sun Pharmaceutical Market Events Screener - Corporate Actions
Get Sun Pharmaceutical corporate actions including splits, bonuses, and buybacks disclosed to the exchange. Check Sun Pharmaceutical stock events that may affect SUNPHARMA share price, along with derivatives, futures and options activity and sector gainers.
15 corporate actions are listed, the most recent entry being Quarterly Result Announcement dated October 30, 2026, with a record date of October 30, 2026.
It is followed by Quarterly Result Announcement dated July 31, 2026 and Annual General Meeting dated July 31, 2026.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2026-10-30 | 2026-10-30 | Quarterly Result Announcement | NA | -0.60% |
| 2026-07-31 | 2026-07-31 | Quarterly Result Announcement | NA | 3.20% |
| 2026-07-31 | 2026-07-31 | Annual General Meeting | NA | 12.00% |
| 2026-07-07 | 2026-07-07 | Dividend | ₹ 5.00 /share | 1.16% |
| 2026-05-22 | 2026-05-22 | Quarterly Result Announcement | NA | 2.34% |
| 2026-02-05 | 2026-02-05 | Dividend | ₹ 11.00 /share | 6.83% |
| 2026-01-31 | 2026-01-31 | Quarterly Result Announcement | NA | -4.69% |
| 2025-11-05 | 2025-11-05 | Quarterly Result Announcement | NA | 1.29% |
| 2025-07-31 | 2025-07-31 | Quarterly Result Announcement | NA | 4.32% |
| 2025-07-31 | 2025-07-31 | Annual General Meeting | NA | 0.19% |
| 2025-07-07 | 2025-07-07 | Dividend | ₹ 5.50 /share | -3.17% |
| 2025-05-22 | 2025-05-22 | Quarterly Result Announcement | NA | -0.76% |
| 2025-02-06 | 2025-02-06 | Dividend | ₹ 10.50 /share | 0.82% |
| 2025-01-31 | 2025-01-31 | Quarterly Result Announcement | NA | -1.01% |
| 2025-01-21 | 2025-01-21 | Extraordinary General Meeting | NA | -1.55% |
Sun Pharmaceutical Competitors Screener - Peer Stocks Comparison
Screen SUNPHARMA competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance, from valuation and price target to the future price outlook, for better stock selection in a changing stock market.
The comparison table covers 10 companies in the Healthcare sector, shown with market capitalisation, P/E ratio, revenue, growth, net profit and RSI.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 421,995 | 34.85 | 61,674 | 12.69% | 11,565 | 37.01 |
| Divis Laboratories | 242,758 | 83.68 | 11,067 | 13.95% | 2,568 | 46.92 |
| Torrent Pharmaceuticals | 173,406 | 80.45 | 13,886 | 20.34% | 2,138 | 32.77 |
| Zydus Life Science | 112,020 | 24.42 | 27,658 | 17.64% | 5,026 | 44.73 |
| Laurus Labs | 111,310 | 102.03 | 6,868 | 22.01% | 890 | 60.45 |
| Cipla | 107,049 | 31.90 | 29,045 | 2.24% | 3,870 | 40.32 |
| Dr Reddys Laboratories | 102,916 | 32.30 | 35,059 | 3.90% | 4,158 | 57.84 |
| Aurobindo Pharma | 95,910 | 25.74 | 34,145 | 5.56% | 3,503 | 47.98 |
| Mankind Pharma | 93,988 | 45.45 | 14,636 | 14.85% | 1,938 | 37.77 |
| Lupin | 89,702 | 16.11 | 29,039 | 26.75% | 5,356 | 35.35 |
Sun Pharmaceutical Company Announcements - News & Reports Screener
Screen SUNPHARMA latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis, and review the option chain for related stocks. Compare other stocks in the same sector.
20 recent announcements are listed, the latest dated October 21, 2026.
The next most recent announcements are dated October 20, 2026 and October 20, 2026.
| Date | Update | Actions |
|---|---|---|
| 2026-10-21 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | - |
| 2026-10-20 | Board Meeting Intimation for Consideration And Approval The Unaudited Financial Results For The Quarter And Half Year Ended 30 September 2026 | - |
| 2026-10-20 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |
| 2026-10-19 | Announcement under Regulation 30 (LODR)-Credit Rating | - |
| 2026-10-18 | Announcement under Regulation 30 (LODR)-Resignation of Director | - |
| 2026-10-18 | Board Meeting Outcome for Outcome Of The Board Meeting Held On 12 October 2026 | - |
| 2026-10-07 | Board Meeting Intimation for Consideration And Approval Of The Issuance Of Listed Rated Unsecured Redeemable Non-Convertible Debentures | - |
| 2026-10-06 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | - |
| 2026-10-02 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-10-01 | Shareholder Meeting / Postal Ballot-Notice of Postal Ballot | - |
| 2026-10-01 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | - |
| 2026-09-30 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-09-29 | ESG Overview For FY 2025-26 | - |
| 2026-09-28 | Completion And Result Of Postal Ballot Dated 25 August 2026 | - |
| 2026-09-28 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | - |
| 2026-09-26 | Receipt Of Approval Of The Shareholders For Reclassification Of Shareholder Category | - |
| 2026-09-25 | Closure of Trading Window | - |
| 2026-09-22 | Announcement under Regulation 30 (LODR)-Investor Presentation | - |
| 2026-09-11 | Intimation Under Regulation 30 Of SEBI LODR | - |
| 2026-09-09 | Incorporation Of A Subsidiary Company | - |
Frequently Asked Questions
How is the company valued right now?
The current quote is ₹1,758.00, within a 52-week range of ₹1,589.30 to ₹2,001.10. The P/E ratio is 34.85 and the P/B ratio is 5.05, with earnings per unit of ₹47.80. Market capitalisation stands at ₹421,995.00 Cr and the dividend yield is 0.91%. The company operates in the Healthcare sector, in the Pharmaceuticals industry, so compare these ratios with its sector peers in the table above.
About This Data
Quotes are sourced from the NSE and the BSE. Key statistics were last updated on October 24, 2026. This page covers 10 balance sheet periods, 15 income statement periods, 10 cash flow years and 8 shareholding periods. Information is provided for research and is not investment advice.